Navigation Links
The Cancer Pain Drug Market, Driven by the Continued Dominance of Opioids, Will Increase From $2.3 Billion in 2008 to $3.7 Billion in 2018
Date:11/17/2009

WALTHAM, Mass., Nov. 17 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, driven by the continued dominance of opioids that include immediate-release morphine and novel fast acting opioid reformulations, the cancer pain drug market will increase from $2.3 billion in 2008 to $3.7 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Cancer Pain finds that the market segment for breakthrough pain (acute flares of pain on a background of controlled chronic pain) will experience the most robust annual growth over the next 10 years, increasing by more than 15 percent per year between 2008 and 2018. This is largely due to the launch and ongoing market penetration of several premium-priced novel opioid reformulations that include Cephalon's Fentora/Effentora and ProStrakan/Kyowa Hakko Kirin's Abstral, which are both reformulations of fentanyl. However, owing to generic availability and physician familiarity, older opioids such as immediate-release morphine will continue to dominate breakthrough cancer pain treatment.

"We anticipate that fast acting fentanyl reformulations will enjoy significant uptake in the breakthrough pain market segment," said Decision Resources Analyst Janie Mackay, Ph.D. "However, experts we interviewed indicate that physicians treating cancer pain are often reluctant to prescribe novel therapies because of strict adherence to the World Health Organization pain ladder which advocates the use of older analgesics such as morphine. The upshot of this is that, despite the launch of several novel therapies for breakthrough cancer pain, immediate-release traditional opioids will continue to dominate treatment of breakthrough pain."

The report also finds that, through 2018, two monoclonal antibodies will enter the cancer pain market
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Novel Technology Breaks Through Cancer Pain
8. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
9. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... , Aug. 27, 2014 Higher ... insurance are fuelling the demand for medical devices ... rise of medical tourism, the inflow of patients ... The market will continue its steady ascent as ... age-related and non-communicable diseases, compelling significant investments in ...
(Date:8/26/2014)... plc (NYSE: ACT ), a leading global specialty ... and President of Actavis, will provide an overview and update ... Conference 2014 in New York, NY . ... presentation will take place on Tuesday, September 9, 2014 at ... 109 East 42 nd Street, New York, ...
(Date:8/26/2014)... -- Research and Markets  has announced the addition ... report to their offering. Intranasal drug ... administration of drugs for the treatment of local diseases ... and non-allergic rhinitis and sinusitis. The nose is considered ... and systematic drug delivery. Continuous technological ...
Breaking Medicine Technology:Frost & Sullivan: Change in Demographics and Surge in Domestic Manufacturing Drive Asia-Pacific Medical Devices Market 2Frost & Sullivan: Change in Demographics and Surge in Domestic Manufacturing Drive Asia-Pacific Medical Devices Market 3Frost & Sullivan: Change in Demographics and Surge in Domestic Manufacturing Drive Asia-Pacific Medical Devices Market 4Actavis to Present at Morgan Stanley Global Healthcare Conference 2014 2Global Intranasal Drug Delivery Market 2014-2018: Key Vendors are Becton, Dickinson and Company, GlaxoSmithKline, Johnson & Johnson and Novartis 2Global Intranasal Drug Delivery Market 2014-2018: Key Vendors are Becton, Dickinson and Company, GlaxoSmithKline, Johnson & Johnson and Novartis 3
... Inc. (Nasdaq: BNVI ) announced today the publication ... of tamoxifen on estrogen receptor beta (ERb) gene regulation. ... in Molecular and Cellular Endocrinology, demonstrate that tamoxifen inhibits ... breast cancer cell proliferation. , "Tamoxifen has been ...
... , BEIJING, Oct. 20 /PRNewswire-Asia-FirstCall/ ... "the Company") a leading manufacturer, developer,and distributor of Shengmingsu ... of China (PRC), today announced that the Company consummated,the ... of October,16, 2009. , Yongye ...
Cached Medicine Technology:Bionovo Announces Publication of Data on Potential Increase in Breast Cancer Risk Due to the Inhibitory Effect of Tamoxifen Treatment on Estrogen Receptor Beta 2Bionovo Announces Publication of Data on Potential Increase in Breast Cancer Risk Due to the Inhibitory Effect of Tamoxifen Treatment on Estrogen Receptor Beta 3Yongye International Announces Completion of Restructuring 2Yongye International Announces Completion of Restructuring 3
(Date:8/27/2014)... Lighthouse Payment Services Inc ., ... it will exhibit its image-based lockbox services at the ... convention in beautiful Lake Placid, New York from ... be held at the Lake Placid Convention Center and ... options in addition to a variety of vendors exhibiting ...
(Date:8/27/2014)... CT (PRWEB) August 27, 2014 Do brands ... International is about to shed some light on the topic ... to members of the Brand Activation Association and ... marketing company polled hundreds of consumers to learn what types ... biggest impact on influencing a potential buying decision. While the ...
(Date:8/27/2014)... Beginning in September, K9 Dog Park ... an interactive, fun way for daycare dogs to learn and ... Dog Park Doggy Daycare clients who bring their dogs into ... Clients will be able to watch their dogs compete through ... compete in D.O.G. will win prizes as will the trainers ...
(Date:8/27/2014)... one of the leading purveyors of real and synthetic hair wigs, ... all its products, for the coming Labor Day. , People searching ... hair products in two ways: when they spend more than ... code LABOR10; while when they spend more than $299, they can ... coupon code is needed when securely checkout, there are about 50 ...
(Date:8/27/2014)... They say knowledge is power, and a new UCLA study ... to men making the best decisions about how to treat ... aren,t well educated about their disease have a much more ... that could negatively impact the quality of their care and ... wake-up call for physicians, who can use the findings to ...
Breaking Medicine News(10 mins):Health News:CRN Set To Release Poll Results On What Marketing Tactics Prompt Consumers To Buy 2Health News:K9 Dog Park Announces Launch Of Daycare Olympic Games – D.O.G. 2Health News:K9 Dog Park Announces Launch Of Daycare Olympic Games – D.O.G. 3Health News:K9 Dog Park Announces Launch Of Daycare Olympic Games – D.O.G. 4Health News:UniWigs Is Offering A Big Sale for Labor Day on All Its Products 2Health News:Men who are uneducated about their prostate cancer have difficulty making good treatment choices 2Health News:Men who are uneducated about their prostate cancer have difficulty making good treatment choices 3
... you take to lower cholesterol may help protect against ... followed more than 7,500 women ages 65 years and ... study show more than 3 percent of women who ... 2.1 percent of women who used statin cholesterol-lowering drugs ...
... in a migraine medication study who cheated and took the ... a big favor.// ,A new study shows the medication ... rather than waiting until pain is moderate to severe, as ... on the use of drugs known as serotonin agonists for ...
... answer when it comes to children losing weight. The study ... may actually promote weight gain.,// ,Obesity is a serious ... United States. During the past two decades, the prevalence of ... percent. Dieting to lose weight is common among adolescent girls ...
... protect them against severe strains of the bacterium Streptococcus ... according to a new study.,// ,Researchers from Harvard ... in 16 diverse communities throughout Massachusetts. Results of the ... strain of S. pneumoniae -- a bacterium that causes ...
... options, but new research shows there may be a way to ... among men in the United States -- affecting nearly 200,000 men ... outlived all his family members. "My mom died at 56. My ... brother at 58, and my next one at 67," he tells ...
... the importance of weight control throughout life to control ... low socio-economic status during childhood can also contribute to ... suggested the negative effect of birthweight on systolic blood ... age. Researchers from Royal Free and University College of ...
Cached Medicine News:
... with ease of use make the OM-5 ... Ideal for office or hospital-based urodynamics, the ... cystometry, leak point pressure, or urethral pressure ... make the OM-5 flexible enough to meet ...
Windows-Based Urodynamics for Fast and Straightforward. Testing For Clinics Where Logic and Efficiency are at a Premium...
... The Corkscrew FT II (fully threaded) ... anchor designed to be inserted flush with ... strength and anchor stability. The full thread ... suture anchors with protruding eyelets. Especially advantageous ...
... (fully threaded) is a 5.5 mm diameter ... flush with the cortical bone surface to ... fully threaded design substantially improves pull-out strength ... The fully threaded design prevents anchor pull-back ...
Medicine Products: